Buy, Sell or Hold: Curaleaf Holdings Inc (CURA-CSE)

Home

Daily Stock Opinions and Ratings

Curaleaf Holdings Inc (CURA-CSE)

0.00

-0.00 (0.00%)

116 watching

Nervous markets await Nvidia

Investor Insights

Apr 16, 2025, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Curaleaf Holdings Inc (CURA-CSE) is facing significant challenges in the current market landscape, primarily due to the ongoing legal issues surrounding marijuana legalization in the United States. Experts argue that the company's growth potential is hampered by the federal laws that impose a 100% tax rate on expenses, making it difficult for the company to operate efficiently. Additionally, there are concerns over an oversupply of cannabis products, which could further inhibit profitability. While some analysts believe that changes in U.S. legislation could enhance Curaleaf's investment appeal, the current environment presents too many risks. Consequently, experts do not recommend investing in Curaleaf at this time due to these legal and market uncertainties.

Consensus

Valuation

Overvalued

Similar

Aurora,AAC

RISKY

Large issue with the company is legalizing the products(marijuana). Another worry is the over supply of products in the market. Federal laws against marijuana in USA make it hard to deal with expenses that are not deductible (100% tax rate). Could be a good investment if US legislation changes. In the meantime, would not recommend investing.

TRADE

US rescheduling hasn't happened. Off peak. Fits and starts when there's news. Entrenched opposition. US firms can't deduct expenses like a "legitimate" business, so can't turn a profit. Trader's dream, but not for long term.

DON'T BUY

He deals with 3- to 5-year money, holds it a long time, and rides the growth of the underlying business. Canadian marijuana space is at risk. US landscape is more fertile, better capitalized, better opportunities, and more upside, especially when the US legislation becomes law.

DON'T BUY

Getting more liberalization of cannabis laws state by state in US. Good for multi-state operators like this one. Well positioned. Elephant in room is federal tax laws, but tax relief won't be for a while.

BUY

Allan Tong’s Discover Picks Despite inflation, Curaleaf’s Q2 was rosy with revenue growing 8% to $338 million and adjusted EBITDA rising 2.2% to 25.6% following -1.5% in Q1. Also, management lowered 2022 guidance by cutting capital spending by $25 million to $125 million. Caveats: There’s a lot of competition in any of these territories, so establishing a presence in all corners of the U.S. is crucial. Also, the path to legalization will be unpredictable, given the vagaries of American politics. You can buy Curaleaf now, but be patient. The ride up could take time, but it could soar into hyperspace any moment, too. Curaleaf boasts 10 buys and one hold at an average price target of $12.14, nearly 50% higher. Buy. Read 3 Cannabis Stocks to go Higher for our full analysis.

Unspecified

Cannabis stocks sold off in the U.S. with many companies burning through cash. Curaleaf should continue to be a leader with cash on the balance sheet and generating cash. It is still building its business. There are challenges in the Cannabis market in the U.S. at the moment. Waiting for more legalization legislation.

BUY

MJ-N down this week He has been long in cannabis. It's been a tough week. Most of this ETF is invested in Canadian stocks. Canopy this week just announced it would issue more shares, which will highly dilute shares. Canopy has been eroding capital quickly. A lot of consolidation needs to happen. The top 3-4 Canadian players are losing market share. Look to U.S. names, instead, where valuations are interesting. Names like Curaleaf are trading at low May 2020 valuations.

COMMENT

A bit of a lottery ticket. Good job expanding in US, strong revenue growth, fairly good cash balance, growing organically. US regulatory environment has not improved. US investment firms won't hold cannabis while still illegal. Tide's gone out on the market. Future is promising, but he can't say when. Will be a leader long term. Investors must decide whether to hold or use tax-loss selling.

PAST TOP PICK

(A Top Pick May 04/21, Down 59%) Derating of secular growth stocks due to rising interest rates. Doing all the right things. Delayed US legislative reform. A victim of the environment. Will be a dominant player in years to come.

Unspecified

This was dragged down with the Cannabis sector and delays in U.S. Cannabis legislation. Has good governance and should be one of the winners in this space. Long term growth is good but not so much short term. Chairman and founder owns $800 million in stock. He owns personally but not for clients.

BUY

US multi-state operator (MSO). Most stocks peaked a year ago, and have been in decline since. Continues to grow. Regulatory and structural issues have caused selling pressure. At some point, valuations will catch up. Leader, biggest MSO. The Cadillac.

PAST TOP PICK

(A Top Pick Jan 07/21, Down 40%) Still has confidence in the name. An emerging growth sector with ups and downs. Company strategy plus industry dynamics will make it a long-term winner. Victim of sentiment and legislative delays. Heightened competition. Still buying.

BUY

One of the leaders. Revenue and EBITDA numbers in the sector have been significant; valuations are attractive, and they're growing. Strategy of both building and buying. After tax loss selling, and into next year, more investors should be looking at it. Catalyst from US legislators would be icing on the cake.

BUY

Emerging growth industry that will be very big in time. Will be one of the dominant players. Likes the pullback, along with the valuation. Whole sector has pulled back on sentiment, legislative delays, heightened competition in Florida. When fundamentals improve, but the stock price goes the other way, you buy.

BUY

Got ahead of itself last year. Continues to buy. A likely winner in the new industry. Not currently profitable, due to old laws on the books about expense deductions. This will change, though probably not this year. Regulatory changes will reduce their cost of capital. Upswings will outweigh downswings over time.

Showing 1 to 15 of 29 entries

Curaleaf Holdings Inc(CURA-CSE) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Curaleaf Holdings Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Curaleaf Holdings Inc(CURA-CSE) Frequently Asked Questions

What is Curaleaf Holdings Inc stock symbol?

Curaleaf Holdings Inc is a OTC stock, trading under the symbol CURA-CSE on the (). It is usually referred to as or CURA-CSE

Is Curaleaf Holdings Inc a buy or a sell?

In the last year, 3 stock analysts published opinions about CURA-CSE. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Curaleaf Holdings Inc.

Is Curaleaf Holdings Inc a good investment or a top pick?

Curaleaf Holdings Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Curaleaf Holdings Inc.

Why is Curaleaf Holdings Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Curaleaf Holdings Inc worth watching?

3 stock analysts on Stockchase covered Curaleaf Holdings Inc In the last year. It is a trending stock that is worth watching.

What is Curaleaf Holdings Inc stock price?

On , Curaleaf Holdings Inc (CURA-CSE) stock closed at a price of $.

Most Recent Experts

Stockchase Insights

5i Research

John Ewing

Ewing Morris Investment Partners

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rebecca Teltscher

Newhaven Asset Management

Rick Rule

Rule Investment Media

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Curaleaf Holdings Inc (CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE)

Curaleaf Holdings Inc(CURA-CSE) Rating

Curaleaf Holdings Inc(CURA-CSE) Frequently Asked Questions

What is Curaleaf Holdings Inc stock symbol?

Is Curaleaf Holdings Inc a buy or a sell?

Is Curaleaf Holdings Inc a good investment or a top pick?

Why is Curaleaf Holdings Inc stock dropping?

Is Curaleaf Holdings Inc worth watching?

What is Curaleaf Holdings Inc stock price?

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Stockchase Insights

John Ewing

The Panic-Proof Portfolio (Stockchase Research)

Rebecca Teltscher

Rick Rule